BARD1 Life Sciences Limited (ASX:BD1)
BARD1 Life Sciences Limited (ASX:BD1) is a diagnostics company with a portfolio of innovative diagnostic technologies and products.
BARD1 Life Sciences is focused on developing and commercialising diagnostic solutions based on its BARD1, SubB2M, Molecular NETs and hTERT platforms for healthcare professionals and patients.
The cancer diagnostics portfolio includes the hTERT test used as an adjunct to urine cytology testing and development-stage tests for ovarian, breast, lung, prostate and pancreatic cancers.
BARD1 Life Sciences is also commercialising its Molecular NETs platform for sample preparation and is launching its proprietary EXO-NET™ exosome capture tool for use in research for exosome-based diagnostics and therapeutics.